- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Epix Medical gets public support
MRI contrast agent developer Epix Medical successfully launchedan initial public offering on Jan. 30, netting $13 million fromthe sale of 2 million shares. Initially offered at $7, the stockclosed at $8.75 on Feb. 12.The Cambridge, MA-based company's
MRI contrast agent developer Epix Medical successfully launchedan initial public offering on Jan. 30, netting $13 million fromthe sale of 2 million shares. Initially offered at $7, the stockclosed at $8.75 on Feb. 12.
The Cambridge, MA-based company's main product is MS-325, an MRIcontrast agent designed for the diagnosis of vascular diseases,including coronary artery disease and peripheral vascular disease(SCAN 12/18/96). Epix, formerly known as Metasyn, has formed strategicalliances to develop and commercialize MS-325 with contrast agentproducers Mallinckrodt and Daiichi.
Shaping the Future of Radiology in 2025: Trends, Threats, and Opportunities
January 10th 2025How do we respond to challenges with staff recruitment, cybersecurity, and looming hospital takeovers in radiology? This author assesses key trends in radiology and offers key insights to stay competitive in the field.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.
Surveillance Breast MRI Associated with Lower Risks of Advanced Second Breast Cancers
January 8th 2025After propensity score matching in a study of over 3,000 women with a personal history of breast cancer, researchers found that surveillance breast MRI facilitated a 59 percent lower risk in advanced presentations of second breast cancers.
